They may be talking about Avastin which there was a controversy around a few years ago. IIRC despite being originally used as an anti-cancer treatment it was found to be very effective (as effective as other treatments) for Wet AMD (age-related macular degeneration, a degenerative condition of the retina). The NICE approved drug options for the condition were significantly more expensive.

Some Trusts were attempting to make this the first line treatment as an off-license prescription as it was cheaper and the pharmaceutical companies were trying to sue the Trusts for "not providing NICE approved medications and therefore disadvantaging patients" while simultaneously not seeking to license Avastin for wet AMD.

This was a few years ago so I may have misremembered some details.